NCT07462247 Establishment of Image Database for Early Upper Gastrointestinal Cancer, Precancerous Lesions, and Precancerous Conditions
| NCT ID | NCT07462247 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | Upper Gastrointestinal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-03-11 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-03-11 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to collect magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, CT images, and histopathology results to establish a database for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions.
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants aged ≥ 18 years 2. Patients with early upper gastrointestinal cancer referred for endoscopic submucosal dissection (ESD), or patients with upper gastrointestinal precancerous lesions or precancerous conditions referred for biopsy by esophagogastroduodenoscopy (EGD) 3. Participants who are willing and able to participate in this study, complete all required examinations and follow-up visits, and who have provided written informed consent Exclusion Criteria: 1. Patients who are not eligible for surgery or who refuse any abdominal surgery in case of capsule retention and endoscopic retrieval failure 2. Patients with cardiac pacemaker or other implanted electromedical devices which could interfere with magnetic resonance 3. Suspected or known intestinal stenosis or other known risk factors for capsule retention 4. Patients with dysphagia 5. Pregnancy 6. Allergy to polymeric materials, latex, simethicone, or pronase 7. Patients plan to undergo magnetic resonance imaging examination before excretion of the capsule 8. Patients with any condition that precludes compliance with the study
Contact & Investigator
Jun Pan, MD
PRINCIPAL INVESTIGATOR
Changhai Hospital
Frequently Asked Questions
Who can join the NCT07462247 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Upper Gastrointestinal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07462247 currently recruiting?
Yes, NCT07462247 is actively recruiting participants. Contact the research team at panjun059@163.com for enrollment information.
Where is the NCT07462247 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07462247 clinical trial?
NCT07462247 is sponsored by Changhai Hospital. The principal investigator is Jun Pan, MD at Changhai Hospital. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.